This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

This study has been completed.
Information provided by (Responsible Party):
Sprout Pharmaceuticals, Inc Identifier:
First received: January 16, 2006
Last updated: March 14, 2012
Last verified: March 2012
To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.

Condition Intervention Phase
Sexual Dysfunctions, Psychological Drug: Flibanserin Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: 12-month Sustained Efficacy of Flibanserin v Placebo n Younger Women With HSDD in NA

Resource links provided by NLM:

Further study details as provided by Sprout Pharmaceuticals, Inc:

Primary Outcome Measures:
  • Duration of efficacy of flibanserin in Sexually Satisfying Events [ Time Frame: 24 weeks ]

Enrollment: 749
Study Start Date: January 2006
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Flibanserin
    flibanserin flexible dosing

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women over 18 and pre-menopausal
  2. FSDS-R above 14
  3. Willingness to try to have sexual activity at least monthly
  4. Willingness to use an electronic diary daily
  5. Stable, monogamous, heterosexual relationship for at least one year
  6. Medically acceptable method of contraception

Exclusion Criteria:

  1. Clinically relevant conditions which might interfere with the patient's abil ity to participate in the trial
  2. Specified medications
  3. Sexual function affected by medication
  4. Drug dependence or abuse
  5. Sexual partner needing treatment
  6. Peri-Menopause or Menopause (surgical or otherwise)
  7. Pregnancy
  8. Pelvic Inflammatory Disease
  9. Major depressive Episode
  10. Significant ECG abnormalities
  11. Significant Neurologic findings
  12. Significant GI, Hepatic, Cardiovascular, Renal, Hematologic, Immunologic or Respiratory findings
  13. Uncorrected thyroid or endocrine disease
  14. Uncontrolled Glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00277914

  Show 65 Study Locations
Sponsors and Collaborators
Sprout Pharmaceuticals, Inc
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Sprout Pharmaceuticals, Inc Identifier: NCT00277914     History of Changes
Other Study ID Numbers: 511.74
Study First Received: January 16, 2006
Last Updated: March 14, 2012

Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological
Mental Disorders processed this record on July 21, 2017